The innovative evolution of cancer gene and cellular therapies

被引：12
|
作者：
Lam, P. [1 ]
Khan, G. [2 ]
Stripecke, R. [3 ]
Hui, K. M. [1 ,4 ,5 ]
Kasahara, N. [6 ]
Peng, K-W [7 ]
Guinn, B-A [2 ,8 ,9 ]
机构：
[1] Natl Canc Ctr, Div Cellular & Mol Res, Singapore, Singapore
[2] Univ Bedfordshire, Dept Life Sci, Luton LU1 3JU, Beds, England
[3] Hannover Med Sch, Lymphat Cell Therapy Program, Excellence Cluster Regenerat Biol REBIRTH, Hannover, Germany
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore
[5] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[7] Mayo Clin, Dept Mol Med, Rochester, MN USA
[8] Univ Southampton, Canc Sci Unit, Southampton Univ Hosp, Southampton, Hants, England
[9] Kings Coll London, Dept Haematol Med, Sch Med, London WC2R 2LS, England
来源：
CANCER GENE THERAPY | 2013年 / 20卷 / 03期
关键词：
stem cells; immunotherapy; cancer research; TARGETED ONCOLYTIC POXVIRUS; T-CELLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; LYMPHOCYTES; RECURRENCE; ACTIVATION; VECTORS; DIFFERENTIATION; 5-FLUOROURACIL;
D O I：
10.1038/cgt.2012.93
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
We provide an overview of the latest developments in cancer gene therapy-from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field. Cancer Gene Therapy (2013) 20, 141-149; doi:10.1038/cgt.2012.93; published online 1 February 2013
引用
收藏
页码：141 / 149
页数：9
相关论文
共 50 条
  • [41] The use of innovative payment mechanisms for gene therapies in Europe and the USA
    Jorgensen, Jesper
    Kefalas, Panos
    REGENERATIVE MEDICINE, 2021, 16 (04) : 405 - 422
  • [42] The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
    Davis, Lucy
    Miller, Rowan E.
    Wong, Yien Ning Sophia
    CANCERS, 2023, 15 (19)
  • [43] Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?
    Tomatsu, Shunji
    Azario, Isabella
    Sawamoto, Kazuki
    Pievani, Alice Silvia
    Biondi, Andrea
    Serafini, Marta
    JOURNAL OF INHERITED METABOLIC DISEASE, 2016, 39 (02) : 189 - 202
  • [44] Trojan horse at cellular level for tumor gene therapies
    Collet, Guillaume
    Grillon, Catherine
    Nadim, Mahdi
    Kieda, Claudine
    GENE, 2013, 525 (02) : 208 - 216
  • [45] Cellular and gene therapies .1. Regulatory health
    Chew, NJ
    BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1995, 8 (08): : 22 - &
  • [46] Cellular and gene therapies face a manufacturing capacity crunch
    Rader, Ronald A.
    Pharmaceutical Technology, 2020, 44 (10) : 56 - 59
  • [47] Cellular and Gene Therapies Face a Manufacturing Capacity Crunch
    Rader, Ronald A.
    BIOPHARM INTERNATIONAL, 2020, 33 (09) : 46 - 49
  • [48] REGULATORY REVIEW OF CELLULAR AND GENE THERAPIES - AN OVERVIEW OF THE PROCESS
    MARTI, GE
    BAUER, S
    PURI, RK
    NOGUCHI, PD
    TRANSFUSION SCIENCE, 1994, 15 (04): : 323 - 329
  • [49] Cellular and gene therapies .2. Off the RAC
    Chew, NJ
    BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1996, 9 (01): : 20 - &
  • [50] Innovative therapies
    Stawowy, P.
    Fleck, E.
    KARDIOLOGE, 2011, 5 (06): : 409 - 410
12345